Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep;81(2):367–375. doi: 10.1038/sj.bjc.6690702

Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311

A M Burger 1, T C Jenkins 2, J A Double 3, M C Bibby 3
PMCID: PMC2362878  PMID: 10496367

Abstract

C1311 is a novel therapeutic agent with potent activity against experimental colorectal cancer that has been selected for entry into clinical trial. The compound has previously been shown to have DNA-binding properties and to inhibit the catalytic activity of topoisomerase II. In this study, cellular uptake and mechanisms by which C1311 interacts with DNA and exerts cytotoxic effects in intact colon carcinoma cells were investigated. The HT29 colon cancer cell line was chosen to follow cellular distribution of C1311 over a time course of 24 h at drug concentrations that just inhibited cell proliferation by 50% or 100%. Nuclear uptake of C1311 and co-localization with lysosomal or mitochondrial dyes was examined by fluorescence microscopy and effects on these cellular compartments were determined by measurement of acid phosphatase levels, rhodamine 123 release or DNA-binding behaviour. The strength and mode of DNA binding was established by thermal melting stabilization, direct titration and viscometric studies of host duplex length. The onset of apoptosis was followed using a TUNEL assay and DNA-fragmentation to determine a causal relationship of cell death. Growth inhibition of HT29 cells by C1311 was concomitant with rapid drug accumulation in nuclei and in this context we showed that the compound binds to duplex DNA by intercalation, with likely A/T sequence-preferential binding. Drug uptake was also seen in lysosomes, leading to lysosomal rupture and a marked increase of acid phosphatase activity 8 h after exposure to C1311 concentrations that effect total growth inhibition. Moreover, at these concentrations lysosomal swelling and breakdown preceded apoptosis, which was not evident up to 24 h after exposure to drug. Thus, the lysosomotropic effect of C1311 appears to be a novel feature of this anticancer agent. As it is unlikely that C1311-induced DNA damage alone would be sufficient for cytotoxic activity, lysosomal rupture may be a critical component for therapeutic efficacy. © 1999 Cancer Research Campaign

Keywords: C1311, HT29 cells, colorectal cancer, cytotoxicity, DNA intercalation, lysosomes

Full Text

The Full Text of this article is available as a PDF (523.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agbandje M., Jenkins T. C., McKenna R., Reszka A. P., Neidle S. Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives. J Med Chem. 1992 Apr 17;35(8):1418–1429. doi: 10.1021/jm00086a010. [DOI] [PubMed] [Google Scholar]
  2. Allison A. C. Lysosomes in cancer cells. J Clin Pathol Suppl (R Coll Pathol) 1974;7:43–50. [PMC free article] [PubMed] [Google Scholar]
  3. Augustin E., Wheatley D. N., Lamb J., Konopa J. Imidazoacridinones arrest cell-cycle progression in the G2 phase of L1210 cells. Cancer Chemother Pharmacol. 1996;38(1):39–44. doi: 10.1007/s002800050445. [DOI] [PubMed] [Google Scholar]
  4. Bailly C., Pommery N., Houssin R., Henichart J. P. Design, synthesis, DNA binding, and biological activity of a series of DNA minor-groove-binding intercalating drugs. J Pharm Sci. 1989 Nov;78(11):910–917. doi: 10.1002/jps.2600781106. [DOI] [PubMed] [Google Scholar]
  5. Beckwith M., Urba W. J., Longo D. L. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J Natl Cancer Inst. 1993 Mar 17;85(6):483–488. doi: 10.1093/jnci/85.6.483. [DOI] [PubMed] [Google Scholar]
  6. Berger B., Marquardt H., Westendorf J. Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Cancer Res. 1996 May 1;56(9):2094–2104. [PubMed] [Google Scholar]
  7. Boyer M. J., Tannock I. F. Lysosomes, lysosomal enzymes, and cancer. Adv Cancer Res. 1993;60:269–291. doi: 10.1016/s0065-230x(08)60828-3. [DOI] [PubMed] [Google Scholar]
  8. Burger A. M., Double J. A., Konopa J., Bibby M. C. Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Br J Cancer. 1996 Nov;74(9):1369–1374. doi: 10.1038/bjc.1996.551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Burger A. M., Kaur G., Alley M. C., Supko J. G., Malspeis L., Grever M. R., Sausville E. A. Tyrphostin AG17, [(3,5-Di-tert-butyl-4-hydroxybenzylidene)- malononitrile], inhibits cell growth by disrupting mitochondria. Cancer Res. 1995 Jul 1;55(13):2794–2799. [PubMed] [Google Scholar]
  10. Chaires J. B., Dattagupta N., Crothers D. M. Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. Biochemistry. 1982 Aug 17;21(17):3933–3940. doi: 10.1021/bi00260a005. [DOI] [PubMed] [Google Scholar]
  11. Cholody W. M., Martelli S., Konopa J. Chromophore-modified antineoplastic imidazoacridinones. Synthesis and activity against murine leukemias. J Med Chem. 1992 Jan 24;35(2):378–382. doi: 10.1021/jm00080a026. [DOI] [PubMed] [Google Scholar]
  12. Cholody W. M., Martelli S., Paradziej-Lukowicz J., Konopa J. 5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. J Med Chem. 1990 Jan;33(1):49–52. doi: 10.1021/jm00163a009. [DOI] [PubMed] [Google Scholar]
  13. Firestone R. A., Pisano J. M., Bonney R. J. Lysosomotropic agents. 1. Synthesis and cytotoxic action of lysosomotropic detergents. J Med Chem. 1979 Sep;22(9):1130–1133. doi: 10.1021/jm00195a026. [DOI] [PubMed] [Google Scholar]
  14. Green D. R., Reed J. C. Mitochondria and apoptosis. Science. 1998 Aug 28;281(5381):1309–1312. doi: 10.1126/science.281.5381.1309. [DOI] [PubMed] [Google Scholar]
  15. Haq I., Ladbury J. E., Chowdhry B. Z., Jenkins T. C., Chaires J. B. Specific binding of hoechst 33258 to the d(CGCAAATTTGCG)2 duplex: calorimetric and spectroscopic studies. J Mol Biol. 1997 Aug 15;271(2):244–257. doi: 10.1006/jmbi.1997.1170. [DOI] [PubMed] [Google Scholar]
  16. Hickman J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 1992 Sep;11(2):121–139. doi: 10.1007/BF00048059. [DOI] [PubMed] [Google Scholar]
  17. Jenkins T. C. Optical absorbance and fluorescence techniques for measuring DNA-drug interactions. Methods Mol Biol. 1997;90:195–218. doi: 10.1385/0-89603-447-X:195. [DOI] [PubMed] [Google Scholar]
  18. Kuśnierczyk H., Chołody W. M., Paradziej-Lukowicz J., Radzikowski C., Konopa J. Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones. Arch Immunol Ther Exp (Warsz) 1994;42(5-6):415–423. [PubMed] [Google Scholar]
  19. Lamb J., Wheatley D. N. Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation. Br J Cancer. 1996 Nov;74(9):1359–1368. doi: 10.1038/bjc.1996.550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Loontiens F. G., Regenfuss P., Zechel A., Dumortier L., Clegg R. M. Binding characteristics of Hoechst 33258 with calf thymus DNA, poly[d(A-T)], and d(CCGGAATTCCGG): multiple stoichiometries and determination of tight binding with a wide spectrum of site affinities. Biochemistry. 1990 Sep 25;29(38):9029–9039. doi: 10.1021/bi00490a021. [DOI] [PubMed] [Google Scholar]
  21. Majno G., Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 1995 Jan;146(1):3–15. [PMC free article] [PubMed] [Google Scholar]
  22. McConnaughie A. W., Jenkins T. C. Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity. J Med Chem. 1995 Sep 1;38(18):3488–3501. doi: 10.1021/jm00018a009. [DOI] [PubMed] [Google Scholar]
  23. McGhee J. D., von Hippel P. H. Theoretical aspects of DNA-protein interactions: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice. J Mol Biol. 1974 Jun 25;86(2):469–489. doi: 10.1016/0022-2836(74)90031-x. [DOI] [PubMed] [Google Scholar]
  24. Nicholson K. M., Bibby M. C., Phillips R. M. Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. Eur J Cancer. 1997 Jul;33(8):1291–1298. doi: 10.1016/s0959-8049(97)00114-7. [DOI] [PubMed] [Google Scholar]
  25. Overgaard J. Effect of hyperthermia on malignant cells in vivo. A review and a hypothesis. Cancer. 1977 Jun;39(6):2637–2646. doi: 10.1002/1097-0142(197706)39:6<2637::aid-cncr2820390650>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  26. Pilch D. S., Waring M. J., Sun J. S., Rougée M., Nguyen C. H., Bisagni E., Garestier T., Hélène C. Characterization of a triple helix-specific ligand. BePI (3-methoxy-7H-8-methyl-11- [(3'-amino)propylamino]-benzo[e]pyrido[4,3-b]indole) intercalates into both double-helical and triple-helical DNA. J Mol Biol. 1993 Aug 5;232(3):926–946. doi: 10.1006/jmbi.1993.1440. [DOI] [PubMed] [Google Scholar]
  27. Quintana J. R., Lipanov A. A., Dickerson R. E. Low-temperature crystallographic analyses of the binding of Hoechst 33258 to the double-helical DNA dodecamer C-G-C-G-A-A-T-T-C-G-C-G. Biochemistry. 1991 Oct 22;30(42):10294–10306. doi: 10.1021/bi00106a030. [DOI] [PubMed] [Google Scholar]
  28. Simon S., Roy D., Schindler M. Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1128–1132. doi: 10.1073/pnas.91.3.1128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Skladanowski A., Plisov S. Y., Konopa J., Larsen A. K. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol. 1996 May;49(5):772–780. [PubMed] [Google Scholar]
  30. Suh D., Chaires J. B. Criteria for the mode of binding of DNA binding agents. Bioorg Med Chem. 1995 Jun;3(6):723–728. doi: 10.1016/0968-0896(95)00053-j. [DOI] [PubMed] [Google Scholar]
  31. Vega M. C., García Sáez I., Aymamí J., Eritja R., Van der Marel G. A., Van Boom J. H., Rich A., Coll M. Three-dimensional crystal structure of the A-tract DNA dodecamer d(CGCAAATTTGCG) complexed with the minor-groove-binding drug Hoechst 33258. Eur J Biochem. 1994 Jun 15;222(3):721–726. doi: 10.1111/j.1432-1033.1994.tb18917.x. [DOI] [PubMed] [Google Scholar]
  32. Yang J., Liu X., Bhalla K., Kim C. N., Ibrado A. M., Cai J., Peng T. I., Jones D. P., Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997 Feb 21;275(5303):1129–1132. doi: 10.1126/science.275.5303.1129. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES